The US Institute for Clinical and Economic Review (ICER) has announced plans to develop a report assessing the comparative clinical effectiveness and value of Novartis’ (NOVN: VX) AVXS-101 and Biogen’s (Nasdaq: BIIB) Spinraza (nusinersen) for treatment of spinal muscular atrophy (SMA).
The ICER’s report is set to be reviewed during a March 2019 meeting of the New England Comparative Effectiveness Public Advisory Council ( New England CEPAC), one of ICER’s three independent evidence appraisal committees.
Nusinersen was approved in 2016 for treatment of SMA in both children and adults, and in the second quarter of 2018 notched up sales of $423 million globally. AVXS-101 is a gene therapy currently being studied for use in infants with SMA, and many analysts expect US Food and Drug Administration approval of this treatment to occur in the first quarter of 2019. The formal scope of ICER’s review – including the drugs reviewed, special subpopulations of interest, and basic approach to economic modeling – will be finalized with the benefit of input from all stakeholders, including clinical experts and patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze